What is Greenwich LifeSciences Financial Strength?
Greenwich LifeSciences has the Financial Strength Rank of 10. It shows strong financial strength and is unlikely to fall into distressed situations.
Good Sign:
Greenwich LifeSciences Inc shows strong financial strength.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:
1. The debt burden that the company has as measured by its
Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3.
Altman Z-Score.
Greenwich LifeSciences has no long-term debt (1).
As of today, Greenwich LifeSciences's Altman Z-Score is 0.00.
(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
Competitive Comparison of Greenwich LifeSciences's Financial Strength
For the Biotechnology subindustry, Greenwich LifeSciences's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Greenwich LifeSciences's Financial Strength Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Greenwich LifeSciences's Financial Strength distribution charts can be found below:
* The bar in red indicates where Greenwich LifeSciences's Financial Strength falls into.
Greenwich LifeSciences Financial Strength Calculation
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
Greenwich LifeSciences's Interest Expense for the
months ended in Dec. 2023 was $0.00 Mil. Its Operating Income for the
months ended in Dec. 2023 was $-2.84 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.00 Mil.
Greenwich LifeSciences's Interest Coverage for the quarter that ended in Dec. 2023 is
| Greenwich LifeSciences had no long-term debt (1). |
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Greenwich LifeSciences Inc has no debt.
2. Debt to revenue ratio. The lower, the better.
Greenwich LifeSciences's Debt to Revenue Ratio for the quarter that ended in Dec. 2023 is
3. Altman Z-Score.
Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
The zones of discrimination were as such:
When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.
Greenwich LifeSciences has a Z-score of 0.00, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Greenwich LifeSciences (Greenwich LifeSciences) Business Description
Traded in Other Exchanges
N/A
Address
3992 Bluebonnet Drive, Building 14, Stafford, TX, USA, 77477
Greenwich LifeSciences Inc is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. Its Product Candidates include; GP2, a HER2/neu transmembrane peptide that elicits a targeted immune response against HER2/neu-expressing cancers, GM-CSF Immunoadjuvant has been shown to enhance monocyte and neutrophil cytotoxicity against melanoma tumor cells and to enhance activity-dependent cellular cytotoxicity of monocytes and neutrophils against targets coated with the anti-ganglioside antibodies, and Cancer immunotherapy seeks to stimulate an individual's immune system to selectively attack cancer cells in order to inhibit the spread of cancer.
Executives
| Snehal Patel |
director, officer: CHIEF EXECUTIVE OFFICER |
2311 SPARTAN TRAIL, SUGAR LAND TX 77479 |
| Jaye Thompson |
officer: VPC AND REGULATORY AFFAIRS |
2408 TIMBERLOCH PLACE, B-7, THE WOODLANDS TX 77380 |
| Frank Joseph Daugherty |
director, officer: CHIEF MEDICAL OFFICER |
2311 SPARTAN TRAIL, SUGAR LAND TX 77479 |
| Kenneth Hallock |
director |
2311 SPARTAN TRAIL, SUGAR LAND TX 77479 |
| David Mcwilliams |
director |
2575 WEST BELLFORT STREET, HOUSTON TX 77054-9816 |
| Eric Rothe |
director |
2311 SPARTAN TRAIL, SUGAR LAND TX 77479 |
| Kinnary Patel |
10 percent owner |
3992 BLUEBONNET DR., BUILDING 14, STAFFORD TX 77477 |
| Panjaj Amrit Patel |
10 percent owner |
50726 LAKESIDE DRIVE, GRANGER IN 46530 |
Greenwich LifeSciences (Greenwich LifeSciences) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
GLSI has been successfully added to your